The effects of vitamin D repletion on endothelial function and inflammation in patients with coronary artery disease.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

The objective of this pilot trial was to investigate the effects of vitamin D repletion on endothelial function and inflammation in patients with coronary artery disease (CAD).

Who Took Part

According to the abstract, 90 subjects were involved.

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and pilot study.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the subjects nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.

It is described as a pilot, a small early test of whether a larger Vitamin D, K2, Magnesium and Zinc study would be practical.

Endothelial function (reactive hyperemia peripheral arterial tonometry, RH-PAT), circulating adhesion molecules, and pro-inflammatory cytokines were measured at baseline and 12 weeks.

What Was Measured

The subject headings attached to it are Biomarkers, Cell Adhesion Molecules, Coronary Artery Disease, Dietary Supplements, Endothelium, Vascular, Hyperemia and Inflammation.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 90 subjects.

The publication is from 2012 (Vascular medicine (London, England)), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.